Sun Pharmaceutical Industries Limited

This study tests a new weekly injection called GL0034 in 285 adults with type 2 diabetes who are overweight or obese. Participants will receive either the study drug or a placebo for about 36 weeks to see if it safely lowers blood sugar levels. The goal is to find a new treatment…

This study follows pregnant women who take tildrakizumab for approved conditions and compares them to pregnant women with the same condition who do not take the drug. Researchers track pregnancy outcomes and infant health up to one year after birth. The goal is to understand if t…